Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A Q1 FY2025 earnings call

Management Statement and Operational Highlights

• Business Progress: Bruker had a solid start to 2025 with double-digit reported and constant exchange rate (CER) revenue growth, 5.1% organic revenue growth in the Bruker Scientific Instruments (BSI) segment, and better operating margin performance than expected.
• New Products: Launched innovative products in spatial biology, cellular analysis, NMR, microbiology, and molecular diagnostics at key conferences (AGBT, ENC, ESCMID, AACR), strengthening high-value offerings in strategic focus areas.
• U.S. Policy and Tariffs Impact: Estimated $100 million gross revenue headwind in 2025 from U.S. ACA/GOV market weakness, China tariffs, and slow China stimulus funding release. Mitigation actions include new pricing, cost-cutting initiatives, and supply chain reengineering to offset over half the headwind in 2025 and fully by 2026.
• Financials: Q1 2025 reported revenue $801.4 million, up 11% year-over-year; organic revenue growth 2.9%; non-GAAP operating margin 12.7%; non-GAAP diluted EPS $0.47, down from $0.53 in Q1 2024.

Segment Performance

• BioSpin: Q1 revenue was $208 million with mid-teens percentage CER growth. Driven by strong ACA/GOV revenue, biopharma environment, preclinical imaging, and lab automation (new Chemspeed business).
• CALID Group: Q1 revenue of $280 million with mid-20s percentage CER growth. Led by microbiology, infection diagnostics, life science mass spectrometry (timsTOF platform), strong in Europe, Americas, clinical, industrial, and biopharma applications; ACA/GOV performance moderate.
• Bruker Annual Revenue: $257 million, high single-digit CER revenue growth. Supported by inorganic revenue growth from NanoString, APAC ex-China, biopharma, and ACA/GOV; offset by softness in Europe, China, X-ray, and nano analysis tools.
• BEST: CER revenues declined high teens percentage net of intercompany eliminations. Research instruments had weaker performance, and the superconductor market for clinical MRI was soft.

Guidance

• Revenue: Reported revenue guidance for 2025 is $3.48 billion to $3.55 billion (3.5%-5.5% growth), with organic revenue growth 0-2%, a ~1% tailwind from foreign exchange, and acquisitions contributing ~2.5%; net headwind of ~$80 million from policy changes and tariffs.
• EPS: Non-GAAP EPS guidance for 2025 is $2.40 to $2.48; constant exchange rate EPS growth expected to be 5%-8% for 2025.
• Quarterly Outlook: Q2 2025 organic revenue expected to decline low single digits, with CER revenue growth in the low single digits year-over-year; non-GAAP operating margin and EPS to decrease transiently in Q2, with significant improvements expected in the second half of 2025.

Risks

• Geopolitical Risks: Uncertainties from U.S. policy changes affecting academic research funding, delays in China stimulus funding release, and new tariffs impacting revenue and margins.
• Market Uncertainties: Softness in Europe, China, X-ray, and nano analysis tools; uncertainty around U.S. pharma tariffs potentially slowing drug discovery and development market recovery.

Question and Answer

Q: Could you elaborate if there was any pull forward in the quarter because of the tariffs worries or any other worries in the market that the customers might have had? And are you baking any impact from that as a result of that pull forward? And in China, I appreciate you mentioned cancellations, but are you seeing any cancellations in the U.S. or European markets, specifically maybe around UHF gigahertz magnets?

A: There really wasn’t any pull forward that’s being talked about due to tariffs or ACA/GOV. We didn’t see that. However, we acknowledge that the UK 1.2 gigahertz system that we had expected for Q2 just went in easily and got in Q1. To cancellations, we don’t really see any China cancellations yet. Customers are in a holding pattern due to import duties, but no cancellations seen in U.S. or European markets yet.

Q: When we think about the offsets, obviously a lot of challenges in the market today. But when we think about the offsets, the AI chips on shoring of that, the funding initiatives in Germany, maybe lower interest rates. Can you walk us through how are you thinking about some of those offsets, potentially sort of mitigating the impact maybe into the second half?

A: AI remains strong in our tools, with TSMC as a large customer. German, Korean, and European stimulus funding and defense spending are positive trends but will have a larger impact in 2026 and beyond. AI-driven bookings were strong in Q1, and onshoring in various regions plays a role, though visibility on tariffs remains uncertain.

Q: Good morning, guys. Maybe one more on the tariff side. Encouraging to hear you guys offsetting that for 2026. Can you just talk through, it sounds like pricing, cost initiatives moving to manufacturing around supply chain management. Can you just talk through, I guess, the new pricing assumptions, what you’re doing on the manufacturing side?

A: We are taking pricing actions, exploring supply chain alternatives like using third-party contract manufacturers in regions like Malaysia, Europe, and the U.S., and implementing significant cost-cutting initiatives (~$30 million this year). Supply chain reengineering has a delayed effect but will be more impactful in 2026. Pricing actions are strategic and not across the board, while supply chain adjustments aim to mitigate tariff impacts.